625 related articles for article (PubMed ID: 22549451)
21. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Keidar S; Gamliel-Lazarovich A; Kaplan M; Pavlotzky E; Hamoud S; Hayek T; Karry R; Abassi Z
Circ Res; 2005 Oct; 97(9):946-53. PubMed ID: 16179584
[TBL] [Abstract][Full Text] [Related]
22. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.
Cheng XW; Murohara T; Kuzuya M; Izawa H; Sasaki T; Obata K; Nagata K; Nishizawa T; Kobayashi M; Yamada T; Kim W; Sato K; Shi GP; Okumura K; Yokota M
Am J Pathol; 2008 Aug; 173(2):358-69. PubMed ID: 18583318
[TBL] [Abstract][Full Text] [Related]
23. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat.
Whaley-Connell A; Govindarajan G; Habibi J; Hayden MR; Cooper SA; Wei Y; Ma L; Qazi M; Link D; Karuparthi PR; Stump C; Ferrario C; Sowers JR
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E355-63. PubMed ID: 17440033
[TBL] [Abstract][Full Text] [Related]
25. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.
Kassiri Z; Zhong J; Guo D; Basu R; Wang X; Liu PP; Scholey JW; Penninger JM; Oudit GY
Circ Heart Fail; 2009 Sep; 2(5):446-55. PubMed ID: 19808375
[TBL] [Abstract][Full Text] [Related]
26. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats.
de Resende MM; Kauser K; Mill JG
Life Sci; 2006 May; 78(26):3066-73. PubMed ID: 16413583
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Hirono Y; Yoshimoto T; Suzuki N; Sugiyama T; Sakurada M; Takai S; Kobayashi N; Shichiri M; Hirata Y
Endocrinology; 2007 Apr; 148(4):1688-96. PubMed ID: 17218415
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.
Watanabe R; Suzuki J; Wakayama K; Kumagai H; Ikeda Y; Akazawa H; Komuro I; Isobe M
Hypertens Res; 2016 Apr; 39(4):237-44. PubMed ID: 26657004
[TBL] [Abstract][Full Text] [Related]
29. Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling.
Ochiai K; Hu Q; Lee J; Mansoor A; Liu J; Wang X; Gong G; Murakami Y; Ishibashi Y; Shimada T; Zhang J
J Cardiovasc Pharmacol; 2006 May; 47(5):686-94. PubMed ID: 16775509
[TBL] [Abstract][Full Text] [Related]
30. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction.
Katada J; Meguro T; Saito H; Ohashi A; Anzai T; Ogawa S; Yoshikawa T
Circulation; 2005 May; 111(17):2157-64. PubMed ID: 15851599
[TBL] [Abstract][Full Text] [Related]
31. Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure.
Okuda N; Hayashi T; Mori T; Inamoto S; Okabe M; Mieno S; Horimoto H; Kitaura Y
Hypertens Res; 2005 May; 28(5):431-8. PubMed ID: 16156507
[TBL] [Abstract][Full Text] [Related]
32. Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.
Matsumoto R; Yoshiyama M; Omura T; Kim S; Nakamura Y; Izumi Y; Akioka K; Iwao H; Takeuchi K; Yoshikawa J
Circ J; 2004 Apr; 68(4):376-82. PubMed ID: 15056838
[TBL] [Abstract][Full Text] [Related]
33. The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction.
Marques Neto SR; da H Silva A; dos Santos MC; Ferraz EF; Nascimento JH
Acta Physiol (Oxf); 2013 Jun; 208(2):166-71. PubMed ID: 23279762
[TBL] [Abstract][Full Text] [Related]
34. Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.
Endo S; Mori T; Yoneki Y; Nakamichi T; Hosoya T; Ogawa S; Tokudome G; Hosoya T; Miyata T; Ito S
Hypertens Res; 2009 Jun; 32(6):513-9. PubMed ID: 19407824
[TBL] [Abstract][Full Text] [Related]
35. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Gabor A; Leenen FH
Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
[TBL] [Abstract][Full Text] [Related]
36. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Toyonaga J; Tsuruya K; Ikeda H; Noguchi H; Yotsueda H; Fujisaki K; Hirakawa M; Taniguchi M; Masutani K; Iida M
Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
[TBL] [Abstract][Full Text] [Related]
37. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
[TBL] [Abstract][Full Text] [Related]
38. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
Mulder P; Mellin V; Favre J; Vercauteren M; Remy-Jouet I; Monteil C; Richard V; Renet S; Henry JP; Jeng AY; Webb RL; Thuillez C
Eur Heart J; 2008 Sep; 29(17):2171-9. PubMed ID: 18586661
[TBL] [Abstract][Full Text] [Related]
39. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
[TBL] [Abstract][Full Text] [Related]
40. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
